United States Federal Circuit
Biogen Idec, Inc. v. GlaxoSmithKline LLC, 2012-1120
In an infringement action involving a drug to treat Chronic Lymphocytic Leukemia, the District Court's construction of the claim term "anti-CD20 antibody" is affirmed where it did not err in finding a clear and unmistakable disclaimer.
Appellate Information
- Decided 04/16/2013
- Published 04/16/2013
Judges
- Reyna
Court
- United States Federal Circuit